These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30587450)

  • 41. Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
    Jiang F; Wang HJ; Jin YH; Zhang Q; Wang ZH; Jia JM; Liu F; Wang L; Bao QC; Li DD; You QD; Xu XL
    J Med Chem; 2016 Dec; 59(23):10498-10519. PubMed ID: 27933959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
    Zhou Y; Wang Y; Zhang L; Tang C; Feng B
    Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
    Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
    Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Oda K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3441-6. PubMed ID: 27390068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
    Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119.
    Nieto A; Fernández-Vega V; Spicer TP; Sturchler E; Adhikari P; Kennedy N; Mandat S; Chase P; Scampavia L; Bannister T; Hodder P; McDonald PH
    Assay Drug Dev Technol; 2018 Jul; 16(5):278-288. PubMed ID: 30019946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
    Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
    Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
    Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
    Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
    Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
    Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. En route to an efficient catalytic asymmetric synthesis of AS-3201.
    Mashiko T; Hara K; Tanaka D; Fujiwara Y; Kumagai N; Shibasaki M
    J Am Chem Soc; 2007 Sep; 129(37):11342-3. PubMed ID: 17722933
    [No Abstract]   [Full Text] [Related]  

  • 56. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU
    Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists.
    Dai X; Stamford A; Liu H; Neustadt B; Hao J; Kowalski T; Hawes B; Xu X; Baker H; O'Neill K; Woods M; Tang H; Greenlee W
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5291-4. PubMed ID: 26433449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists.
    Sato K; Sugimoto H; Rikimaru K; Imoto H; Kamaura M; Negoro N; Tsujihata Y; Miyashita H; Odani T; Murata T
    Bioorg Med Chem; 2014 Mar; 22(5):1649-66. PubMed ID: 24508142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.
    Semple G; Ren A; Fioravanti B; Pereira G; Calderon I; Choi K; Xiong Y; Shin YJ; Gharbaoui T; Sage CR; Morgan M; Xing C; Chu ZL; Leonard JN; Grottick AJ; Al-Shamma H; Liang Y; Demarest KT; Jones RM
    Bioorg Med Chem Lett; 2011 May; 21(10):3134-41. PubMed ID: 21444206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.